Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Urinary Tract Infections Therapeutics market. The report identifies the key trends shaping and driving the global Urinary Tract Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Urinary Tract Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Urinary Tract Infections Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Urinary Tract Infections Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Urinary Tract Infections Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Urinary Tract Infections Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Urinary Tract Infections Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Urinary Tract Infections Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Urinary Tract Infections Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Urinary Tract Infections Therapeutics market landscape? – Identify, understand and capitalize.
Therapy Industry in the United Kingdom
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 UTI Therapeutics - Introduction 7
2.1 Overview 7
2.2 Classification of UTI 7
2.2.1 Site of Infection 8
2.2.2 Based On Symptoms 8
2.2.3 Based on Recurrence 8
2.2.4 Based on Complicating Factors 8
2.2.5 Based on Origin of Infection 8
2.3 Epidemiology 9
2.4 Etiology 10
2.5 Risk Factors 10
2.6 Signs and Symptoms 11
2.7 Pathophysiology of UTI 11
2.8 Diagnosis and Treatment of UTI 12
2.9 GlobalData Pipeline Report Guidance 16
3 UTI Therapeutics - Market Characterization 17
3.1 UTI Therapeutics Market Size (2005-2010) - Global 17
3.2 UTI Therapeutics Market Forecast (2010-2018) - Global 19
3.3 UTI Therapeutics Market Size (2005-2010) - The US 21
3.4 UTI Therapeutics Market Forecast (2010-2018) - The US 22
3.5 UTI Therapeutics Market Size (2005-2010) - France 23
3.6 UTI Therapeutics Market Forecast (2010-2018) - France 24
3.7 UTI Therapeutics Market Size (2005-2010) - Germany 25
3.8 UTI Therapeutics Market Forecast (2010-2018) - Germany 26
3.9 UTI Therapeutics Market Size (2005-2010) - Italy 27
3.10 UTI Therapeutics Market Forecast (2010-2018) - Italy 28
3.11 UTI Therapeutics Market Size (2005-2010) - Spain 29
3.12 UTI Therapeutics Market Forecast (2010-2018) - Spain 30
3.13 UTI Therapeutics Market Size (2005-2010) - The UK 31
3.14 UTI Therapeutics Market Forecast (2010-2018) - The UK 32
3.15 UTI Therapeutics Market Size (2005-2010) - Japan 33
3.16 UTI Therapeutics Market Forecast (2010-2018) - Japan 34
3.17 Drivers and Barriers for the UTI Therapeutics Market 35
3.17.1 Drivers for the UTI Therapeutics Market 35
3.17.2 Barriers for the UTI Therapeutics Market 35
3.18 Key Events Impacting the Future Market 36
3.19 Opportunity and Unmet Need 36
3.20 Key Takeaway 37
4 UTI Therapeutics Market - Competitive Assessment 38
4.1 Overview 38
4.1.1 Strategic Competitor Assessment 38
4.2 Profiles of Commonly Used Products in the UTI Therapeutics Market 39
4.2.1 Ciprofloxacin 39
4.2.2 Doribax (doripenem) 40
4.2.3 Invanz (ertapenem sodium) 41
4.2.4 Levaquin (levofloxacin) 42
4.2.5 Fosfomycin tromethamine 42
4.2.6 Macrobid/Macrodantin (nitrofurantoin) 43
4.2.7 Bactrim/Septra (trimethoprim/sulfamethoxazole) 44
4.3 Key Takeaway 44
5 UTI Therapeutics Market - Pipeline Assessment 45
5.1 Overview 45
5.2 Strategic Pipeline Assessment 45
5.2.1 UTI Therapeutics - Phase III Pipeline 46
5.2.2 UTI Therapeutics - Phase II Pipeline 46
5.2.3 UTI Therapeutics – Phase I Pipeline 46
5.3 UTI Pipeline by Mechanism of Action 47
5.4 UTI Technology Trends Analytical Framework 48
5.5 UTI Therapeutics - Late-stage Drugs under Clinical Development 49
5.6 Molecule Profile for Late-stage Drugs under Clinical Development 50
5.6.1 CXA-201 (CXA-101/tazobactam) 50
5.6.2 CAZ-AVI (Avibactam/ceftazidime) 50
5.7 Key Takeaway 51
6 UTI Therapeutics - Clinical Trials Mapping 52
6.1 Clinical Trials by Country (US, EU5 and Japan) 52
6.2 Clinical Trials by Phase 53
6.3 Clinical Trials by Trial Status 54
6.4 Overall Sponsors 55
6.5 Prominent Sponsors 56
6.6 Top Companies Participating in UTI Therapeutics Clinical Trials 57
7 UTI Therapeutics - Strategic Assessment 58
7.1 UTI Therapeutics - Implications for Future Market Competition 58
8 UTI Therapeutics - Future Players 59
8.1 Introduction 59
8.1.1 AstraZeneca PLC 59
8.1.2 Cubist Pharmaceuticals 61
8.1.3 Forest Laboratories 63
9 UTI Therapeutics - Licensing and Partnership Deals 65
10 UTI Therapeutics - Appendix 67
10.1 Definitions 67
10.2 Acronyms 67
10.3 Research Methodology 68
10.3.1 Coverage 68
10.3.2 Secondary Research 68
10.3.3 Forecasting 69
10.3.4 Primary Research 71
10.3.5 Expert Panel Validation 71
10.4 Contact Us 71
10.5 Disclaimer 71
10.6 Bibliography 72
List of Tables
Table 1: UTI - Prevalence, Major Markets, 2010 9
Table 2: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17
Table 3: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19
Table 4: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21
Table 5: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22
Table 6: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23
Table 7: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24
Table 8: UTI Therapeutics Market, Germany, Revenue ($m), 2005-2010 25
Table 9: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26
Table 10: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27
Table 11: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28
Table 12: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29
Table 13: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30
Table 14: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31
Table 15: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32
Table 16: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33
Table 17: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34
Table 18: UTI Therapeutics - Phase III Pipeline 46
Table 19: UTI Therapeutics - Phase II Pipeline 46
Table 20: UTI Therapeutics – Phase I Pipeline 46
Table 21: UTI Therapeutics - Late-stage Drugs Under Clinical Development, 2011 49
Table 22: UTI Therapeutics - Clinical Trials by Country, 2011 52
Table 23: UTI Therapeutics - Clinical Trials by Phase, 2011 53
Table 24: UTI Therapeutics - Clinical Trials by Status, 2011 54
Table 25: UTI Therapeutics, Overall Sponsors, 2011 55
Table 26: UTI Therapeutics - Prominent Sponsors, 2011 56
Table 27: UTI Therapeutics - Top Companies Participating in Clinical Trials, 2011 57
Table 28: AstraZeneca Infectious Disease Pipeline, 2011 61
Table 29: Cubist Pharmaceuticals Infectious Disease Pipeline, 2011 62
Table 30: Forest Laboratories - Infectious Disease Pipeline, 2011 64
Table 31: Licensing and Partnership Deals 65
List of Figures
Figure 1: Classification of UTI 7
Figure 2: Principal Pathogens of UTI 10
Figure 3: Symptoms of UTI 11
Figure 4: Diagnostic Approach to UTI in Adults 12
Figure 5: Different Class of Antibiotics Used for UTI 13
Figure 6: Diagnosis and Treatment of UTI 14
Figure 7: Diagnosis and Treatment of UTI 15
Figure 8: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 17
Figure 9: UTI Therapeutics, Market Share ($m, %), 2010 18
Figure 10: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 19
Figure 11: UTI Therapeutics, Market Share ($m, %), 2018 20
Figure 12: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 21
Figure 13: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 22
Figure 14: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 23
Figure 15: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 24
Figure 16: UTI Therapeutics Market, Germany , Revenue ($m), 2005-2010 25
Figure 17: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 26
Figure 18: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 27
Figure 19: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 28
Figure 20: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 29
Figure 21: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 30
Figure 22: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 31
Figure 23: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 32
Figure 24: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 33
Figure 25: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 34
Figure 26: UTI Therapeutics Market , Key Events Impacting the Future Market 36
Figure 27: Opportunity and Unmet Need in the UTI Therapeutics Market, 2011 37
Figure 28: UTI Therapeutics - Strategic Competitor Assessment, 2011 39
Figure 29: UTI Therapeutics - Pipeline by Phase of Clinical Development, 2011 45
Figure 30: UTI Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 47
Figure 31: Technology Trends Analytical Framework of the UTI Pipeline, 2011 48
Figure 32: Technology Trends Analytical Framework of The UTI Therapeutics Pipeline - Description, 2011 49
Figure 33: UTI Therapeutics - Clinical Trials by Country, 2011 52
Figure 34: UTI Therapeutics - Clinical Trials by Phase, 2011 53
Figure 35: UTI Therapeutics - Clinical Trials by Status, 2011 54
Figure 36: UTI Therapeutics - Overall Sponsors, 2011 55
Figure 37: UTI Therapeutics - Prominent Sponsors, 2011 56
Figure 38: UTI Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 57
Figure 39: Implications for Future Market Competition in the UTI Therapeutics Market, 2011 58
Figure 40: UTI Therapeutics Market - Clinical Pipeline by Company, 2011 59
Figure 41: GlobalData Market Forecasting Model 70
Companies mentioned
AstraZeneca PLC
Cubist Pharmaceuticals
Forest Laboratories
